Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.52 |
| ▸ | GGT1 | P19440 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.37 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.35 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.35 |
| ▸ | GSR | P00390 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.33 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8191952 | 1.00 | GABRR1 (0.52) | GABRR1GGT1ALDH1A1MEN1LMNA | |
| SCHEMBL7027611 | 0.88 | FOLH1 (0.46) | GABRR1GGT1ALDH1A1MEN1LMNA | |
| SCHEMBL3725106 | 0.88 | FOLH1 (0.46) | GABRR1GGT1ALDH1A1MEN1LMNA | |
| SCHEMBL7027613 | 0.88 | FOLH1 (0.46) | GABRR1GGT1ALDH1A1MEN1LMNA | |
| SCHEMBL209237 | 0.86 | FOLH1 (0.53) | GABRR1FOLH1GSRCPB2RNPEP | |
| SCHEMBL1413149 | 0.86 | FOLH1 (0.53) | GABRR1FOLH1GSRCPB2RNPEP | |
| SCHEMBL3727817 | 0.86 | FOLH1 (0.53) | GABRR1FOLH1GSRCPB2RNPEP | |
| SCHEMBL26731701 | 0.83 | GABRR1 (0.41) | GABRR1GABBR2GABBR1 | |
| SCHEMBL757850 | 0.83 | GABRR1 (0.41) | GABRR1GABBR2GABBR1 | |
| SCHEMBL8197321 | 0.82 | ALDH1A1 (0.41) | GABRR1ALDH1A1MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138361-B2 | C-10 carbamates of taxanes | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100016238-A1 | Peptides for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20100016238-A1 | Peptides for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20100016237-A1 | Novel Peptides for Use in the Treatment of Obesity | NOVO NORDISK A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20090306014-A1 | C-10 CARBAMATES OF TAXANES | ACIDOPHIL LLC (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2008087187-A1 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008087186-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016238-A1 | Peptides for Use in the Treatment of Obesity | MC4R, GIPR, MC3R | GABRR1 686/4885GGT1 3167/4885ALDH1A1 4095/4885 |
| US-20100016237-A1 | Novel Peptides for Use in the Treatment of Obesity | MC4R, MC3R, GIPR | GABRR1 693/4885GGT1 3089/4885ALDH1A1 3915/4885 |
| US-20090306014-A1 | C-10 CARBAMATES OF TAXANES | CASP10, S100A10, ATXN10 | GABRR1 3968/4885GGT1 2506/4885ALDH1A1 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.